Synopsis
0
VMF
DRUG PRODUCT COMPOSITIONS0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
With Virupaksha, you get a quality product with on-time delivery.
Certificate Number : CEP 2022-032 - Rev 00
Status : Valid
Issue Date : 2024-05-13
Type : Chemical
Substance Number : 2733
Venkar Chemicals – WHO-GMP & ISO Certified API Experts Delivering Global Standards.
Certificate Number : CEP 2022-163 - Rev 00
Status : Valid
Issue Date : 2024-06-25
Type : Chemical
Substance Number : 2733
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - TABLET;ORAL - EQ 10MG BASE
USFDA APPLICATION NUMBER - 21323
DOSAGE - TABLET;ORAL - EQ 20MG BASE
USFDA APPLICATION NUMBER - 21323
DOSAGE - TABLET;ORAL - EQ 5MG BASE
USFDA APPLICATION NUMBER - 21323
DOSAGE - SOLUTION;ORAL - EQ 5MG BASE/5ML **Fe...DOSAGE - SOLUTION;ORAL - EQ 5MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 21365
Related Excipient Companies
EUROAPI
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Minakem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Rochem International Inc
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]SPI Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Boai NKY Pharmaceuticals Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Well Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pfanstiehl
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kirsch Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Dr. Paul Lohmann GmbH & Co. KGaA
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ACG Worldwide
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Actylis
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Aeon Procare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Anhui Sunhere Pharmaceutical Excipients Co.,Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ashland
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CD Formulation
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Clariant
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Corel Pharma Chem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DFE Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Esteem Industries
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Finar
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gloria Interchem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ideal Cures
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ingredion Pharma Solutions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kerry
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Keval Exports
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kima Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Lonza Capsugel
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Microlex e.U
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Bold Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Neelkanth MineChem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nitika Pharmaceutical Specialities
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nomisma Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Novo Excipients
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pharmatrans-Sanaq
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pluviaendo
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Prachin Pharmachem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Qianhao Chemical (Hebei) Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Qualicaps
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Roquette
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Seppic
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Shenmei Pharmaceutical Technology Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shijiazhuang Huaxu Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Sigachi Industries
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Silverline Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]The Dow Chemical Company
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Valens Pharmachem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Vasa Pharmachem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Zhejiang Huakang Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Fillers, Diluents & Binders
Coating Systems & Additives
Thickeners and Stabilizers
Direct Compression
Solubilizers
Granulation
Controlled & Modified Release
Parenteral
Film Formers & Plasticizers
Disintegrants & Superdisintegrants
Topical
Taste Masking
Chewable & Orodispersible Aids
Co-Processed Excipients
Lubricants & Glidants
API Stability Enhancers
Emulsifying Agents
Rheology Modifiers
Empty Capsules
Surfactant & Foaming Agents
Vegetarian Capsules
Coloring Agents
Soft Gelatin
Digital Content
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
84
PharmaCompass offers a list of Escitalopram Oxalate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Escitalopram Oxalate manufacturer or Escitalopram Oxalate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Escitalopram Oxalate manufacturer or Escitalopram Oxalate supplier.
A ECT-12003 (S-CITALOPRAM OXALATE) manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of ECT-12003 (S-CITALOPRAM OXALATE), including repackagers and relabelers. The FDA regulates ECT-12003 (S-CITALOPRAM OXALATE) manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. ECT-12003 (S-CITALOPRAM OXALATE) API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of ECT-12003 (S-CITALOPRAM OXALATE) manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A ECT-12003 (S-CITALOPRAM OXALATE) supplier is an individual or a company that provides ECT-12003 (S-CITALOPRAM OXALATE) active pharmaceutical ingredient (API) or ECT-12003 (S-CITALOPRAM OXALATE) finished formulations upon request. The ECT-12003 (S-CITALOPRAM OXALATE) suppliers may include ECT-12003 (S-CITALOPRAM OXALATE) API manufacturers, exporters, distributors and traders.
click here to find a list of ECT-12003 (S-CITALOPRAM OXALATE) suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
A ECT-12003 (S-CITALOPRAM OXALATE) DMF (Drug Master File) is a document detailing the whole manufacturing process of ECT-12003 (S-CITALOPRAM OXALATE) active pharmaceutical ingredient (API) in detail. Different forms of ECT-12003 (S-CITALOPRAM OXALATE) DMFs exist exist since differing nations have different regulations, such as ECT-12003 (S-CITALOPRAM OXALATE) USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A ECT-12003 (S-CITALOPRAM OXALATE) DMF submitted to regulatory agencies in the US is known as a USDMF. ECT-12003 (S-CITALOPRAM OXALATE) USDMF includes data on ECT-12003 (S-CITALOPRAM OXALATE)'s chemical properties, information on the facilities and procedures used, and details about packaging and storage. The ECT-12003 (S-CITALOPRAM OXALATE) USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of ECT-12003 (S-CITALOPRAM OXALATE) suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The ECT-12003 (S-CITALOPRAM OXALATE) Drug Master File in Japan (ECT-12003 (S-CITALOPRAM OXALATE) JDMF) empowers ECT-12003 (S-CITALOPRAM OXALATE) API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the ECT-12003 (S-CITALOPRAM OXALATE) JDMF during the approval evaluation for pharmaceutical products. At the time of ECT-12003 (S-CITALOPRAM OXALATE) JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of ECT-12003 (S-CITALOPRAM OXALATE) suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a ECT-12003 (S-CITALOPRAM OXALATE) Drug Master File in Korea (ECT-12003 (S-CITALOPRAM OXALATE) KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of ECT-12003 (S-CITALOPRAM OXALATE). The MFDS reviews the ECT-12003 (S-CITALOPRAM OXALATE) KDMF as part of the drug registration process and uses the information provided in the ECT-12003 (S-CITALOPRAM OXALATE) KDMF to evaluate the safety and efficacy of the drug.
After submitting a ECT-12003 (S-CITALOPRAM OXALATE) KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their ECT-12003 (S-CITALOPRAM OXALATE) API can apply through the Korea Drug Master File (KDMF).
click here to find a list of ECT-12003 (S-CITALOPRAM OXALATE) suppliers with KDMF on PharmaCompass.
A ECT-12003 (S-CITALOPRAM OXALATE) CEP of the European Pharmacopoeia monograph is often referred to as a ECT-12003 (S-CITALOPRAM OXALATE) Certificate of Suitability (COS). The purpose of a ECT-12003 (S-CITALOPRAM OXALATE) CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of ECT-12003 (S-CITALOPRAM OXALATE) EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of ECT-12003 (S-CITALOPRAM OXALATE) to their clients by showing that a ECT-12003 (S-CITALOPRAM OXALATE) CEP has been issued for it. The manufacturer submits a ECT-12003 (S-CITALOPRAM OXALATE) CEP (COS) as part of the market authorization procedure, and it takes on the role of a ECT-12003 (S-CITALOPRAM OXALATE) CEP holder for the record. Additionally, the data presented in the ECT-12003 (S-CITALOPRAM OXALATE) CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the ECT-12003 (S-CITALOPRAM OXALATE) DMF.
A ECT-12003 (S-CITALOPRAM OXALATE) CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. ECT-12003 (S-CITALOPRAM OXALATE) CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of ECT-12003 (S-CITALOPRAM OXALATE) suppliers with CEP (COS) on PharmaCompass.
A ECT-12003 (S-CITALOPRAM OXALATE) written confirmation (ECT-12003 (S-CITALOPRAM OXALATE) WC) is an official document issued by a regulatory agency to a ECT-12003 (S-CITALOPRAM OXALATE) manufacturer, verifying that the manufacturing facility of a ECT-12003 (S-CITALOPRAM OXALATE) active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting ECT-12003 (S-CITALOPRAM OXALATE) APIs or ECT-12003 (S-CITALOPRAM OXALATE) finished pharmaceutical products to another nation, regulatory agencies frequently require a ECT-12003 (S-CITALOPRAM OXALATE) WC (written confirmation) as part of the regulatory process.
click here to find a list of ECT-12003 (S-CITALOPRAM OXALATE) suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing ECT-12003 (S-CITALOPRAM OXALATE) as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for ECT-12003 (S-CITALOPRAM OXALATE) API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture ECT-12003 (S-CITALOPRAM OXALATE) as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain ECT-12003 (S-CITALOPRAM OXALATE) and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a ECT-12003 (S-CITALOPRAM OXALATE) NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of ECT-12003 (S-CITALOPRAM OXALATE) suppliers with NDC on PharmaCompass.
ECT-12003 (S-CITALOPRAM OXALATE) Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of ECT-12003 (S-CITALOPRAM OXALATE) GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right ECT-12003 (S-CITALOPRAM OXALATE) GMP manufacturer or ECT-12003 (S-CITALOPRAM OXALATE) GMP API supplier for your needs.
A ECT-12003 (S-CITALOPRAM OXALATE) CoA (Certificate of Analysis) is a formal document that attests to ECT-12003 (S-CITALOPRAM OXALATE)'s compliance with ECT-12003 (S-CITALOPRAM OXALATE) specifications and serves as a tool for batch-level quality control.
ECT-12003 (S-CITALOPRAM OXALATE) CoA mostly includes findings from lab analyses of a specific batch. For each ECT-12003 (S-CITALOPRAM OXALATE) CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
ECT-12003 (S-CITALOPRAM OXALATE) may be tested according to a variety of international standards, such as European Pharmacopoeia (ECT-12003 (S-CITALOPRAM OXALATE) EP), ECT-12003 (S-CITALOPRAM OXALATE) JP (Japanese Pharmacopeia) and the US Pharmacopoeia (ECT-12003 (S-CITALOPRAM OXALATE) USP).
